Lonza's chairman has ruled out plans to use its capacity to fill syringes and provide final production steps for new obesity drugs even as rivals scramble for a share of the booming weight-loss market. That marks a climb down from remarks at an investor event a month ago, when Albert Baehny said that Lonza would participate in the obesity therapy market thanks to its growing fill and finish capacity. The new obesity drugs, based on a class of peptides known as glucagon-like peptide-1 (GLP-1) receptor agonists, would not feature in Lonza's growth plans, despite the Swiss company producing a secondary ingredient for one such drug, Baehny said in an interview.
Coronavirus: Pfizer BioNTech To Produce COVID-19 Vaccines In South Africa ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.
Reuters
Published: 23 Apr 2021 05:29 PM BdST
Updated: 23 Apr 2021 05:29 PM BdST Johnson & Johnson s coronavirus disease (COVID-19) vaccines are kept refrigerated at the Forem vaccination centre in Pamplona, Spain, Apr 22, 2021. REUTERS
Johnson & Johnson s single-shot COVID-19 vaccine is expected to be imported to India for fill and finish by June or July, financial daily Mint reported on Friday, citing ANI. );
}
Fill and finish is the final step in the manufacturing process of putting the vaccine into vials or syringes, sealing them and packaging them up for shipping.
India has said it would fast-track emergency approvals for COVID-19 vaccines authorised by Western countries and Japan, paving the way for possible imports of Pfizer, Johnson & Johnson and Moderna shots.
Read more about UK Govt. extends contract with Wockhardt for manufacture of COVID-19 vaccines on Business Standard. Powered by Capital Market - Live News
Wockhardt rose 1.96% to Rs 529.70 after the drug company announced that it has been awarded a six-month extension of its agreement with the UK Government to fill-finish COVID-19 vaccines.This expands the original agreement from 18 to 24 months i.e., until August 2022 and the manufacturing will continue to be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.
In the UK, Wockhardt is one of the largest suppliers into the U.K. s National Health service (NHS) for over 20 years, has had a presence in Wrexham for over two decades and employs over 400 people at its 612,000 square feet high-tech manufacturing facility.